The therapeutic potential of TNF-α blockade in rheumatoid arthritis

Bibliography

• LAWRENCE RC, HOCHBERG MC, KELSEY JL et al.: Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. Rheumatol (1989) 16:427–441.
   Web of Science ®Google Scholar
• HARRIS ED Jr: Pathogenesis of rheumatoid arthritis. Am. I Med. (1986) 80:4–10.
   Web of Science ®Google Scholar
• GABRIEL SE, CROWSON CS, KREMERS HM et al.: Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritic Rheum. (2003) 48:54–58.
   PubMed Web of Science ®Google Scholar
• VAN DOORNUM S, MCCOLL G, WICKS IP: Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritic Rheum. (2002) 46:862–873.
   Google Scholar
• SOLOMON DH, KARLSON EW, RIMM EB et al.: Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation (2003) 107:1303–1307.
   PubMed Web of Science ®Google Scholar
• YELIN E: Arthritis. The cumulative impact of a common chronic condition. Arthritic Rheum. (1992) 35:489–497.
   Google Scholar
• LEE DM, WEINBLATT ME: Rheumatoid arthritis. Lancet (2001) 358:903–911.
   PubMed Web of Science ®Google Scholar
• ROSS R: Atherosclerosis-an inflammatory disease. N Engl. Med. (1999) 340:115–126.
   PubMed Web of Science ®Google Scholar
• DAYERJM, DE ROCHEMONTEIX B,BURRUS B, DEMCZUK S, DINARELLO CA: Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells. Clin. Invest. (1986) 77:645–648.
   Google Scholar
• BUCALA R, RITCHLIN C, WINCHESTER R, CERAMI A: Constitutive production of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts. Exp. Med. (1991) 173:569–574.
   PubMed Web of Science ®Google Scholar
• DI GIOVINE FS, NUKI G, DUFF GW: Tumour necrosis factor in synovial exudates. Ann. Rheum. Dis. (1988) 47:768–772.
   PubMed Web of Science ®Google Scholar
• CHU CQ, FIELD M, FELDMANN M, MAINI RN: Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. (1991) 34:1125–1132.
   PubMed Web of Science ®Google Scholar
• AREND WP, DAYERJM: Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum. (1990) 33:305–315.
   PubMed Web of Science ®Google Scholar
• •A review describing cytokines and cytokine inhibitors or antagonists expressed in arthritic joints.
   Google Scholar
• AREND WP, DAYERJM: Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum. (1995) 38:151–160.
   PubMed Web of Science ®Google Scholar
• •A review describing cytokines and cytokine inhibitors or antagonists expressed in arthritic joints.
   Google Scholar
• FELDMANN M: Development of anti- TNF therapy for rheumatoid arthritis. Nat. Rev Immunol (2002) 2:364–371.
   PubMed Web of Science ®Google Scholar
• ••A historical article describing in detail thedevelopment of anti-TNF-a biologicals.
   Google Scholar
• FELDMANN M, BRENNAN FM, FOXWELL BM, MAINI RN: The role of TNF alpha and IL-1 in rheumatoid arthritis. Carr. Dir. Autoimmun (2001) 3:188–199.
   PubMedGoogle Scholar
• BRENNAN FM, CHANTRY D, JACKSON AM, MAINI RN, FELDMANN M: Cytokine production in culture by cells isolated from the synovial membrane. Autoimmun. (1989) 2(Suppl.):177–186.
   Google Scholar
• CHU CQ, FIELD M, ALLARD S et al: Detection of cytokines at the cartilage/ pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br: J. Rheumatol. (1992) 31:653–661.
   PubMedGoogle Scholar
• DELEURAN BW, CHU CQ, FIELD M et al.: Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha. Arthritic Rheum. (1992) 35:1170–1178.
   Google Scholar
• BRENNAN FM, CHANTRY D, JACKSON A, MAINI R, FELDMANN M: Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet (1989) 2(8657):244–247.
   PubMed Web of Science ®Google Scholar
• •This is the first report demonstrating that TNF-a blockade reduces inflammatory cytokine production by cultured RA synovial cells.
   Google Scholar
• BUTLER DM, MAINI RN, FELDMANN M, BRENNAN FM: Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Ear: Cytokine Netw. (1995) 6:225–230.
   Google Scholar
• HAWORTH C, BRENNAN FM, CHANTRY D et al.: Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur. Immunol. (1991) 21:2575–2579.
   PubMed Web of Science ®Google Scholar
• WILLIAMS RO, FELDMANN M, MAINI RN: Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Nati Acad. Sci USA (1992) 89:9784–9788.
   PubMed Web of Science ®Google Scholar
• •Publication showing effectiveness of TNF-a blockade in a murine model of arthritis.
   Google Scholar
• PIGUET PF, GRAU GE, VESIN C et a/.: Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology (1992) 77:510–514.
   Google Scholar
• THORBECKE GJ, SHAH R, LEU CH et al.: Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen Type II arthritis in mice. Proc. Nati Acad. Sci. USA (1992) 89:7375–7379.
   PubMed Web of Science ®Google Scholar
• ELLIOTT MJ, MAINI RN, FELDMANN M et al: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritic Rheum. (1993) 36:1681–1690.
   PubMed Web of Science ®Google Scholar
• ••First open-label clinical trial of infliximabin RA.
   Google Scholar
• ELLIOTT MJ, MAINI RN, FELDMANN M et al: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 344:1105–1110.
   PubMed Web of Science ®Google Scholar
• ••Randomised double-blind clinical trial ofinflixirnab in RA.
   Google Scholar
• MAINI RN, BREEDVELD FC, KALDEN JR et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. (1998) 41:1552–1563.
   PubMed Web of Science ®Google Scholar
• MAINI R, ST CLAIR EW, BREEDVELD F et al: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT Study Group. Lancet (1999) 354:1932–1939.
   PubMed Web of Science ®Google Scholar
• CHARLES P, ELLIOTT MJ, DAVIS D et al.: Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J. Immunol. (1999) 163:1521–1528.
   PubMed Web of Science ®Google Scholar
• ULFGREN AK, ANDERSSON U, ENGSTROM M et al.: Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritic Rheum. (2000) 43:2391–2396.
   PubMed Web of Science ®Google Scholar
• PALEOLOG EM, HUNT M, ELLIOTT MJ et al.: Deactivation of vascular endothelium by monoclonal anti- tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritic Rheum. (1996) 39:1082–1091.
   PubMed Web of Science ®Google Scholar
• TAK PP, TAYLOR PC, BREEDVELD FC et al.: Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritic Rheum. (1996) 39:1077–1081.
   PubMed Web of Science ®Google Scholar
• TAYLOR PC, PETERS AM, PALEOLOG E et al.: Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritic Rheum. (2000) 43:38–47.
   PubMed Web of Science ®Google Scholar
• BALLARA SC, MIOTLA JM, PALEOLOG EM: New vessels, new approaches: angiogenesis as a therapeutic target in musculoskeletal disorders. Int. J. Exp. Pathol. (1999) 80:235–250.
   PubMed Web of Science ®Google Scholar
• •Review of the role of angiogenesis in RA.
   Google Scholar
• PALEOLOG EM: Angiogenesis in rheumatoid arthritis. Arthritic Res. (2002) 4\(Suppl. 3):S81–S90.
   Google Scholar
• NEUFELD G, COHEN T, GENGRINOVITCH S, POLTORAK Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. (1999) 13:9–22.
   PubMed Web of Science ®Google Scholar
• FAVA RA, OLSEN NJ, SPENCER-GREEN G et al.: Vascular permeability factor/endothelial growth factor (VPF/ VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. Exp. Med. (1994) 180:341–346.
   PubMed Web of Science ®Google Scholar
• KOCH AE, HARLOW LA, HAINES GK et al.: Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J. Immunol. (1994) 152:4149–4156.
   Google Scholar
• PALEOLOG EM, YOUNG S, STARK AC et al.: Modulation of angiogenic vascular endothelial growth factor (VEGF) by TNFa and IL-1 in rheumatoid arthritis. Arthritic Rheum. (1998) 41:1258–1265.
   PubMed Web of Science ®Google Scholar
• TAYLOR PC: VEGF and imaging of vesselsin rheumatoid arthritis. Arthritic Res. (2002) 4\(Suppl. 3):S99–S107.
   Google Scholar
• LIPSKY PE, VAN DER HEIJDE DM, ST CLAIR EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. (2000) 343:1594–1602.
   Google Scholar
• KALDEN-NEMETH D, GREBMEIER J, ANTONI C et al: NMR monitoring of rheumatoid arthritis patients receiving anti-TNF-alpha monoclonal antibody therapy. Rheumatol Int. (1997) 16:249–255.
   PubMed Web of Science ®Google Scholar
• BRENNAN FM, BROWNE KA, GREEN PA et al.: Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Br. J. Rheumatol (1997) 36:643–650.
   PubMedGoogle Scholar
• MAINI RN, FELDMANN M: How does infliximab work in rheumatoid arthritis? Arthritic Res. (2002) 4\(Suppl. 2):S22–S28.
   Google Scholar
• ••This review summarises the currentunderstanding of the mechanisms of action of inflizirnab in RA.
   Google Scholar
• GENOVESE MC, BATHON JM, MARTIN RW et al.: Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritic Rheum. (2002) 46:1443–1450.
   PubMed Web of Science ®Google Scholar
• WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. (2003) 48:35–45.
   PubMed Web of Science ®Google Scholar
• CHOY EH, ISENBERG DA, GARROOD T et al: Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. (2002) 46:3143–3150.
   PubMed Web of Science ®Google Scholar
• NUKI G, BRESNIHAN B, BEAR MB, MCCABE D: Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2002) 46:2838–2846.
   PubMed Web of Science ®Google Scholar
• FLEISCHMANN RIVI, SCHECHTMAN J, BENNETT R et al.: Ana, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-lra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum. (2003) 48:927–934.
   PubMed Web of Science ®Google Scholar
• KAVANAUGH AF, DAVIS LS, JAIN RI et al.: A Phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis. RheumatoL (1996) 23:1338–1344.
   Web of Science ®Google Scholar
• CHOY EH, PANAYI GS, EMERY P et al.:Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. Rheumatology (Oxford) (2002) 41:1142–1148.
   PubMed Web of Science ®Google Scholar
• PEACOCK DJ, BANQUERIGO ML, BRAHN E: Angiogenesis inhibition suppresses collagen arthritis. I Exp. Med. (1992) 175:1135–1138.
   PubMed Web of Science ®Google Scholar
• OLIVER SJ, CHENG TP, BANQUERIGO ML, BRAHN E: The effect of thalidomide and 2 analogs on collagen induced arthritis. Rheumatol (1998) 25:964–969.
   Web of Science ®Google Scholar
• STORGARD CM, STUPACK DG, JONCZYK A et al: Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J. Clin. Invest. (1999) 103:47–54.
   PubMed Web of Science ®Google Scholar
• MIOTLA J, MACIEWICZ R, KENDREW J, FELDMANN M, PALEOLOG E: Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab. Invest. (2000) 80:1195–1205.
   PubMed Web of Science ®Google Scholar
• LU J, KASAMA T, KOBAYASHI K et al.: Vascular endothelial growth factor expression and regulation of murine collagen-induced arthritis. I Immunol (2000) 164:5922–5927.
   PubMed Web of Science ®Google Scholar
• SUMARIWALLA P, CAO Y, WU H, FELDMANN M, PALEOLOG E: The angiogenesis inhibitor protease-activated kringles 1-5 reduces the severity of murine collagen-induced arthritis. Arthritis Res. Ther (2003) 5:R32–R39.
   PubMed Web of Science ®Google Scholar
• MARGOLIN K, GORDON MS, HOLMGREN E et al.: Phase lb trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin. Oncol (2001) 19:851–856.
   PubMed Web of Science ®Google Scholar
• NAGASHIMA M, YOSHINO S, AONO H, TAKAI M, SASANO M: Inhibitory effects of anti-rheumatic drugs on vascular endothelial growth factor in cultured rheumatoid synovial cells. Clin. Exp. ImmunoL (1999) 116:360–365.
   PubMed Web of Science ®Google Scholar
• NAGASHIMA M, WAUKE K, HIRANO D et al.: Effects of combinations of anti-rheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis. Rheumatology (Oxford) (2000) 39:1255–1262.
   PubMed Web of Science ®Google Scholar
• FELDMANN M, ANDREAKOS E, SMITH C et al.: Is NF-kappaB a useful therapeutic target in rheumatoid arthritis? Ann. Rheum. Dis. (2002) 61\(Suppl. 2):1113-II18.
   Google Scholar
• KIRIAKIDIS S, ANDREAKOS E, MONACO C et al.: VEGF expression in human macrophages is NE-KB-dependent: studies using adenoviruses expressing the endogenous NF-icB inhibitor IxBa and a kinase defective form of the IicB kinase 2. J. Cell ScL (2003) 116:665–674.
   PubMed Web of Science ®Google Scholar
• ANDREAKOS E, SMITH C, KIRIAKIDIS S et al.: Heterogeneous requirement of IicB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis: implications for therapy. Arthritis Rheum. (2003) (In press).
   Google Scholar
• ANDREAKOS E, SMITH C, MONACO C et al.: IicB kinase 2 but not NF-kappa B-inducing kinase is essential for effective DC antigen presentation in the allogeneic mixed lymphocyte reaction. Blood (2003) 101:983–991.
   PubMed Web of Science ®Google Scholar
• CELLETTI FL, HILFIKER PR, GHAFOURI P, DAKE MD: Effect of human recombinant vascular endothelial growth factor 165 on progression of atherosclerotic plaque. J. Am. Coll. Cardiol (2001) 37:2126–2130.
   PubMed Web of Science ®Google Scholar
• TAYLOR P, PATEL S, PALEOLOG E et al.: Reduced synovial vascularity following TNFa blockade in rheumatoid arthritis. Arthritis Rheum. (1998) 41 (Suppl. 9):S295.
   Google Scholar
• DAVIS D, CHARLES PJ, POTTER A et al.: Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor alpha blockade. Br. J. Rheumatol (1997) 36:950-956. Affiliation
   Google Scholar